MENU
XFOR
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

X4 Pharmaceuticals (XFOR) Earnings Date & Reports

X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases... Show more

Industry: #Biotechnology
A.I. Advisor
published Earnings

XFOR is expected to report earnings to rise 23.75% to -19 cents per share on March 23

X4 Pharmaceuticals XFOR Stock Earnings Reports
Q4'26
Est.
$-0.20
Q3'26
Beat
by $0.03
Q2'26
Beat
by $0.06
Q1'26
Missed
by $0.04
Q4'25
Missed
by $0.11
The last earnings report on November 04 showed earnings per share of -15 cents, beating the estimate of -18 cents. With 481.26K shares outstanding, the current market capitalization sits at 315.29M.
A.I.Advisor
Nov 04, 2026

X4 Pharmaceuticals (XFOR) Third Quarter 2026 Earnings Recap: Loss Narrows as Rare-Disease Pipeline Advances

Key Takeaways

  • Revenue reached $2.9 million in the third quarter of 2026, up roughly 63% from $1.8 million a year earlier, driven by XOLREMDI product sales in the United States.
  • Net loss narrowed to $20.2 million, or $(0.16) per share, compared with $29.8 million, or $(0.69) per share, in the same period last year.
  • Results came in ahead of consensus, with the reported loss per share beating analyst estimates of about $(0.19) and revenue exceeding the roughly $2.2 million forecast.
  • The company ended the quarter with $187.7 million in cash, cash equivalents, and marketable securities, and secured a new senior term loan facility of up to $150 million with K2 HealthVentures.
  • Enrollment in the pivotal Phase 3 4WARD trial of mavorixafor in chronic neutropenia remains on track to complete in the fourth quarter of 2026, with topline data expected in the first quarter of 2028.
  • X4 also introduced the 4STEPS Phase 2b trial, designed to evaluate safe reduction of G-CSF (granulocyte colony-stimulating factor) dosing after starting mavorixafor.
  • For more on this ticker's Major News, Today's Price Move, Price Targets, and Forecast, explore the dedicated pages on Tickeron.
  • Discover additional market opportunities by exploring Trending AI Robots.

Earnings Context and Why It Matters

X4 Pharmaceuticals is a commercial-stage biopharmaceutical company focused on rare hematology, or blood-related, diseases. Its sole marketed product, XOLREMDI (mavorixafor), is approved in the United States for WHIM syndrome, a rare primary immunodeficiency. For investors, the quarterly results matter less for the modest current revenue base than for what they signal about the company's larger bet: expanding mavorixafor into chronic neutropenia, a condition marked by abnormally low neutrophil counts that raise infection risk. The third quarter's results arrived alongside meaningful clinical and financial updates, including a restructuring-driven decline in operating expenses, a strengthened cash position, and progress on the pivotal 4WARD trial that underpins the company's long-term commercial ambitions.

Reported Results

For the three months ended September 30, 2026, X4 Pharmaceuticals reported total revenue of $2.9 million, up from $1.8 million in the prior-year period. Net product sales were $2.8 million, entirely from XOLREMDI in the United States, with $0.1 million in license and other revenue tied to the Norgine license and supply agreement. Net loss narrowed to $20.2 million, or $(0.16) per share, compared with a net loss of $29.8 million, or $(0.69) per share, a year earlier. Both figures came in ahead of consensus, which had projected a loss of roughly $(0.19) per share on approximately $2.2 million in revenue.

Expense discipline continued to support the bottom line. Research and development (R&D) expenses fell to $13.3 million from $17.3 million a year ago, while general and administrative (G&A) expenses declined to $9.0 million from $11.6 million, reflecting the 2025 strategic restructuring. For the nine-month period, revenue totaled $14.4 million and the net loss was $56.6 million, or $(0.45) per share. As of September 30, 2026, cash, cash equivalents, and marketable securities stood at $187.7 million.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors following names like XFOR, it offers a structured way to surface comparable opportunities across the biotechnology and healthcare sectors.

Market Reaction and Investor Sentiment

Sentiment around X4 Pharmaceuticals remains tied to its clinical pipeline rather than its modest revenue line. The company has historically drawn a positive stock response after beating expectations: shares rose more than 11% following the August 2026 report and roughly 19% after the March 2026 release, according to market data. The third-quarter update reinforced the themes that have supported that enthusiasm, including progress toward completing 4WARD enrollment by the end of 2026, an optimized trial design following a positive meeting with the U.S. Food and Drug Administration (FDA), and a newly secured term loan that bolsters financial flexibility. Key risks investors are weighing include the typical uncertainties of late-stage clinical trials, the timeline to potential FDA approval, and the company's ongoing reliance on future capital to fund operations.

Forward Outlook and Key Factors to Monitor

The most important catalyst ahead is the 4WARD Phase 3 trial of mavorixafor in primary chronic neutropenia. Management expects to complete enrollment of 126 participants in the fourth quarter of 2026, with topline data anticipated in the first quarter of 2028 and a potential FDA approval in late 2028 or early 2029.

Beyond 4WARD, investors should watch the new 4STEPS Phase 2b trial, which will evaluate whether G-CSF dosing can be safely reduced after starting mavorixafor while maintaining stable neutrophil counts. The first participant is expected to enroll in the first quarter of 2027, with topline data targeted for early 2028.

Financially, the company's $187.7 million cash position and the up to $150 million K2 HealthVentures term loan are designed to support operations well into the future. Investors should continue to monitor expense discipline, the pace of XOLREMDI sales, and any changes to guidance or timelines related to the chronic neutropenia program, as these will shape how the market values the company's pipeline opportunity.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a biotechnology company which engages in developing human antibodies for treating infectious diseases

Industry Biotechnology

Industry
Biotechnology
Address
61 North Beacon Street
Phone
+1 857 529-8300
Employees
45
Web
https://www.x4pharma.com